Is Rapamycin safe to take daily?

Rapamycin is rated "Generally Safe" based on clinical evidence. Always consult your healthcare provider before starting any supplement.

Rapamycin: Benefits, Dosage, Drug Interactions

AVELOR SUMMARY

Rapamycin is a prescription-only mTOR inhibitor, not a dietary supplement, and the honest evidence state is split cleanly in two. Its approved medical uses are well evidenced: an FDA-approved immunosuppressant used in kidney transplant recipients under prescriber supervision, where randomized trials reported lower rates of acute allograft rejection, and, in a 12-month randomized trial of 89 patients with lymphangioleiomyomatosis, it stabilized lung function versus placebo (FEV1 slope 1 plus or minus 2 mL per month versus minus 12 plus or minus 2 mL per month, p<0.001). The longevity hypothesis is a separate and much weaker body of work. The strongest longevity data are animal-only: a 2025 meta-analysis of 911 effect sizes from 167 papers across eight vertebrate species found rapamycin significantly extended lifespan, and genetically heterogeneous mice fed rapamycin starting at 600 days of age lived 14 percent (females) and 9 percent (males) longer at 90 percent mortality. In humans, no trial has ever measured lifespan. The available human data are short-term surrogate studies: mTOR inhibitors modestly improved influenza vaccine response and reduced self-reported infections in older adults, but the largest confirmatory trial (1,024 adults aged 65-plus randomized to RTB101 10mg daily or placebo for 16 weeks) missed its primary endpoint (26 percent versus 25 percent, p=0.65). A 48-week randomized placebo-controlled trial of weekly low-dose rapamycin in healthy adults found it relatively safe but found no change in the primary outcome. Known risks are real: hypercholesterolemia, bone marrow suppression, mouth ulceration, impaired wound healing, immunosuppression, and glucose intolerance in animal models. Rapamycin is a narrow-therapeutic-index CYP3A4 and P-glycoprotein substrate with extensive drug interactions requiring blood level monitoring. Any use of rapamycin, for any purpose, must be decided and supervised by a licensed prescriber. Avelor does not recommend a longevity dose and does not consider off-label longevity use to be established.

WHAT IT DOES

Rapamycin binds the intracellular protein FKBP12, and that complex then inhibits mTOR complex 1 (mTORC1), a nutrient and growth-factor sensing kinase that controls protein synthesis, cell growth, and the rate of autophagy. Inhibiting mTORC1 shifts cells away from anabolic growth and toward recycling of damaged proteins and organelles. Because mTORC1 signaling is one of the pathways whose activity tracks with biological aging in model organisms, mTOR inhibition has been studied as a candidate mechanism for slowing age-related decline, with evidence in mice spanning lifespan, cardiac function, central nervous system measures, immune function, and cellular senescence (Selvarani 2020, PMID: 33037985). That mechanistic story is coherent, and it is also where the honest limit sits: mechanism plausibility is not a human outcome.

The same mechanism produces the risk profile. mTORC1 inhibition suppresses lymphocyte proliferation, which is why the drug is used as an immunosuppressant, and which is why immune-related caution applies in any off-label use. In rodents, chronic mTORC1 inhibition upregulated hepatic gluconeogenesis and impaired lipid deposition in adipose tissue, producing glucose intolerance and hyperlipidemia at trial doses of 2 mg/kg/day for 15 days (Houde 2010, PMID: 20299475), and separately reduced islet mass, insulin content, and insulin sensitivity in mice (Yang 2012, PMID: 22105852). Whether intermittent low-dose regimens avoid this in humans is not established.

Pharmacokinetically, rapamycin is a critical-dose drug: oral bioavailability is low and variable (about 14 percent), the terminal half-life is long at roughly 62 hours, intersubject variability in oral clearance is high, and biotransformation runs through CYP3A4 with P-glycoprotein efflux, which is what drives its extensive drug interaction profile and the standard requirement for therapeutic drug monitoring (MacDonald 2000, PMID: 10823378; Mahalati 2001, PMID: 11523724).

AVELOR SUMMARY

WHAT IT DOES

Rapamycin

AVELOR SUMMARY

WHAT IT DOES

SAFETY PROFILE

Critical Interactions (Do Not Combine Without Medical Supervision)

Moderate Interactions (Monitor Closely)

Theoretical/Low-Risk Interactions

RELATED RESEARCH

Discover More

Rapamycin

AVELOR SUMMARY

WHAT IT DOES

SAFETY PROFILE

Critical Interactions (Do Not Combine Without Medical Supervision)

Moderate Interactions (Monitor Closely)

Theoretical/Low-Risk Interactions

RELATED RESEARCH

Discover More